ArticleThe oncologist2019

U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.

E Dianne Pulte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.